Mounjaro Warnings: What the Evidence and Regulators Say

What regulators have said, and when

The clearest regulatory signal in recent months came on 29 January 2026, when the MHRA published a Drug Safety Update on GLP-1 receptor agonists highlighting acute pancreatitis as an infrequent but potentially serious side effect. The warning is practical: if you develop severe stomach pain that does not ease and seems to move towards your back (with or without vomiting) stop treatment and get emergency help. This applies to tirzepatide specifically as well as to GLP-1 medicines as a class.

Pancreatitis was flagged during the SURMOUNT clinical programme, which enrolled thousands of adults with obesity across its trials. The condition is rare, but because it can escalate quickly it sits at the top of the prescribing warnings, and our Mounjaro warnings page sets out the full list so you can read them in one place before you start. Anyone with a history of pancreatitis should discuss this with their prescriber before starting.

Mounjaro also carries a Black Triangle (▼) designation, meaning the MHRA requires enhanced reporting of suspected side effects. Patients can (and are encouraged to) report anything unexpected through the Yellow Card scheme. That reporting loop is how regulators catch patterns that trials alone cannot.

The thyroid and cancer warning explained clearly

Mounjaro's prescribing information includes a warning about thyroid C-cell tumours. This was observed in rodent studies at doses well above those used in humans, and its relevance to people has not been established. The MHRA and the medicine's SmPC are transparent about the uncertainty rather than dismissing it: that is precisely why anyone with a personal or family history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia type 2 (MEN2) should not use tirzepatide.

For everyone else, there is currently no evidence from human data that Mounjaro causes thyroid cancer. The warning exists as a precaution, not a confirmed signal in the population taking it. If you have concerns about this specifically, our thyroid warning page covers the evidence in detail, and the cancer warning page addresses what is known and what remains uncertain.

The NHS tirzepatide patient information page lists all contraindications in plain language, it is worth reading before you start, and our prescribers go through relevant history at every consultation.

Day-to-day warnings people actually encounter

The most common Mounjaro warnings in practice are gastrointestinal. Nausea tops the list, particularly in the early weeks or after each dose increase. Some people find it peaks in the morning, there is more detail on managing that on the morning nausea page. Vomiting, diarrhoea and constipation also feature. These effects are not trivial when they happen, but they are well-characterised in the SURMOUNT trials and usually ease as the body adjusts.

Dehydration is the practical risk that follows: if GI symptoms are prolonged, drink water consistently throughout the day. If you cannot keep fluids down, that is a prompt to call a clinician, not to wait it out. One thing worth noting about storage, the pen sits in the fridge door, and many people find keeping it visible next to something they open daily makes the weekly injection easier to remember. The SmPC specifies the exact room-temperature window if you need to travel; never guess at it.

On the drug-interaction side, the slowing of gastric emptying is the key mechanism to flag. Oral contraceptive pills may be absorbed more slowly during the first four weeks of treatment and after each dose increase; NHS guidance advises adding a barrier method during those periods. The same absorption concern applies to HRT taken orally, transdermal options like patches or gels are worth discussing with your GP if this applies to you. For a broader view of what to watch for, the full side-effects page covers each one in depth.

Warnings that apply before you start, not just during treatment

Some of Mounjaro's most important warnings are about who should not use it at all. Tirzepatide is not licensed for anyone under 18. It is not recommended during pregnancy, while breastfeeding, or when trying to conceive, women are advised to use effective contraception throughout treatment and for a period afterwards before attempting to get pregnant, in line with MHRA guidance.

Certain conditions are absolute stops: MTC, MEN2, and a history of serious hypersensitivity to tirzepatide or any component of the pen. Others, including a history of pancreatitis, diabetic retinopathy, or certain gallbladder conditions, need careful prescriber assessment rather than automatic exclusion.

If you are considering treatment and want to understand eligibility in full, the Mounjaro overview page covers what the licence covers and what clinical assessment involves. And if you are already on treatment and have a question about a symptom or interaction, our prescribers are available for aftercare seven days a week, the contact page has the details. For those ready to find out whether Mounjaro is clinically right for them, checking eligibility with a free consultation is the next step.